Physician profile
Nuttapoom Yoadjarust
NPI 1447742028
$17,881.10
in general payments reported to CMS, 2019-2025
30 companies · $4,724 in 2025
The $4,724 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,120 · 2022: $2,883 · 2023: $4,269 · 2024: $3,885 · 2025: $4,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Honoraria: $250 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,529.36 |
| Honoraria | $250.00 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,424.41 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $3,420.50 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $2,413.59 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,484.94 | 2021-2025 | Dupixent |
| Kaleo, INC. | $1,145.92 | 2021-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $851.28 | 2021-2025 | |
| Csl Behring | $561.69 | 2024-2025 | Haegarda, Andembry, Kcentra |
| Teva Pharmaceuticals USA, INC. | $543.66 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $435.75 | 2021-2025 | Cuvitru, Takhzyro |
| Amgen INC. | $414.52 | 2022-2025 | Tezspire |
| Alk-Abello, INC | $402.50 | 2021-2025 | Grastek, Ragwitek, Odactra |
| Abbvie INC. | $371.21 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $334.97 | 2021-2024 | |
| Pfizer INC. | $306.35 | 2021-2023 | |
| Organon LLC | $277.05 | 2025 | Vtama |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $237.17 | 2024-2025 | Adbry, Anzupgo |
| Optinose US, INC. | $235.67 | 2021-2025 | |
| Genentech USA, INC. | $189.90 | 2023-2025 | Xolair |
| Hikma Pharmaceuticals USA | $123.28 | 2023-2024 | Ryaltris |
| Sanofi-Aventis U.S. LLC | $98.99 | 2025 | |
| Biocryst US Sales Co., LLC | $89.17 | 2024-2025 | Orladeyo |
| Cycle Pharmaceuticals INC | $81.04 | 2024-2025 | Sajazir |
| Pharming Healthcare, INC. | $78.13 | 2022-2024 | Ruconest |
| Galderma Laboratories, L.P. | $73.30 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $72.09 | 2024-2025 | Ayvakit |
| Incyte Corporation | $65.10 | 2021-2023 | Opzelura |
| Ionis Pharmaceuticals, INC. | $52.85 | 2025 | Dawnzera |
| Inspire Medical Systems, INC. | $47.97 | 2024 | Inspire |
| Grifols USA, LLC | $27.22 | 2025 | Xembify |
| Horizon Therapeutics Plc | $20.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nuttapoom Yoadjarust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.